The effect of MK-927, a topical carbonic anhydrase inhibitor, on IOP in glaucomatous monkeys

References

• Becker B. Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor, diamox. Am. J. Ophthalmol. 1954; 37: 13–15
   PubMed Web of Science ®Google Scholar
• Grant W. M., Trotter R. R. Diamox (acetazolamide) in treatment of glaucoma. Arch. Ophthalmol. 1954; 51: 735–739
   PubMed Web of Science ®Google Scholar
• Becker B., Middleton W. H. Long-term acetazolamide administration in therapy of glaucomas. Arch. Ophthalmol. 1955; 54: 187–192
   Web of Science ®Google Scholar
• Carvalho C. A., Lawrence C., Stone H. H. Acetazclamide (Diamox) therapy in chronic glaucoma. Arch. Ophthalmol. 1958; 59: 840–849
   Google Scholar
• Epstein D. L., Grant W. M. Carbonic anhydrase inhibitor side effects. Arch. Ophthalmol. 1977; 95: 1378–1382
   PubMed Web of Science ®Google Scholar
• Schwam H., Michelson S. R., Sondey J. M., Smith R. L. L-645, 151 a topically effective ocular hypotensive carbonic anhydrase inhibitor: Part I. Biochemistry and metabolism. Invest. Ophthalmol. Vis. Sci. (Suppl.) 1984; 25: 180
   Google Scholar
• Sugrue M. F., Gautheron P., Schmitt C., Viader M. P., Conquet R. L., Smith R. L., Shane N. N., Stone C. A. On the pharmacology of L-645, 151: A topically effective ocular hypotensive carbonic anhydrase inhibitor. J. Pharmacol. Exp. Ther. 1985; 232: 534–540
   PubMed Web of Science ®Google Scholar
• Jankowska L., Maren T. H. Factors affecting the distribution and pharmacology of topically applied carbonic anhydrase inhibitors. Invest. Ophthalmol. Vis. Sci. (Suppl.) 1984; 25: 181
   PubMedGoogle Scholar
• Flach A. J., Peterson J. S., Seligmann K. A. Local ocular hypotensive effect of topically applied acetazolamide. Am. J. Ophthalmol. 1984; 98: 66–72
   PubMed Web of Science ®Google Scholar
• Stein A., Pinke R., Krupin T., Glabb E., Podos S. M., Serle J., Maren T. H. The effect of topically administered carbonic anhydrase inhibitors on aqueous dynamics in rabbits. Am. J. Ophthalmol. 1983; 95: 222–228
   PubMed Web of Science ®Google Scholar
• Maren T. H., Bar-Ilan A. Effect of 6-OH benzo (b) thiophene-2 sulfonamide, a new topical carbonic anhydrase (CA) inhibitor, on intraocular pressure in rabbits. Invest. Ophthalmol. Vis. Sci. (Suppl.) 1987; 28: 268
   Google Scholar
• Lewis R. A., Schoenwald R. D., Eller M. G., Barfknecht C. F., Phelps C D. Ethoxzolamide analog gel: A topical carbonic anhydrase inhibitor. Arch. Ophthalmol. 1984; 102: 1821–1824
   PubMedGoogle Scholar
• Friedman Z., Allen R. C. Ocular hypotensive effect of topical acetazolamide. Invest. Ophthalmol. Vis. Sci. (Suppl.) 1984; 25: 11
   Web of Science ®Google Scholar
• Sugrue M. F., Gautheron P., Grove J., Mallorga P., Schwam H., Viader M. P., Baldwin J. J., Ponticello G. S. MK-927: A topically effective ocular hypotensive carbonic anhydrase (CA) inhibitor in rabbits. Invest. Ophthalmol. Vis. Sci. (Suppl.) 1988; 29: 81
   Google Scholar
• Wistrand P. J., Schenhold M., Ionnerholm G. Carbonic anhydrase isoenzyires CAI and CAII in the human eye. Invest. Ophthalmol. Vis. Sci. 1986; 27: 419–428
   PubMed Web of Science ®Google Scholar
• Lee P-Y., Podos S. M., Howard-Williains J. R., Severin C. H., Rose A. D., Siegel M. J. Pharmacological testing in the laser induced monkey glaucoma model. Curr. Eye. Res. 1985; 4: 775–781
   PubMed Web of Science ®Google Scholar
• Becker B. Friedenwald Memorial Lecture: Carbonic anhydrase and aqueous formation. Am. J. Ophthalmol. 1959; 47: 342–361
   PubMed Web of Science ®Google Scholar
• Friedland B. R., Mallone J., Anderson D. R. Short-term dose response characteristics of acetazolamide in man. Arch. Ophthalmol. 1977; 95: 1809–1812
   PubMed Web of Science ®Google Scholar
• Berson F. G., Epstein D. L., Grant M. W., Hutchinson T., Dobbs P. C. Acetazolamide dosage forms in the treatment of glaucoma. Arch. Ophthalmol. 1980; 98: 1051–1054
   PubMed Web of Science ®Google Scholar
• Foss R. H. local application of Diamox. Am. J. Ophthalmol. 1955; 39: 336–339
   PubMed Web of Science ®Google Scholar
• Green H., Bocher C A., Calnan A. F., Leopold I. H. Carbonic anhydrase and the maintenance of intraocular tension. Arch. Ophthalmol. 1955; 53: 463–471
   Google Scholar
• Green H., Leopold I. H. Effects of locally administered Diamox. Am. J. Ophthalmol. 1955; 40: 137–139
   PubMed Web of Science ®Google Scholar
• Gloster J., Perkins E. S. Effects of carbonic anhydrase inhibitor (Diamox) on intraocular pressure of rabbits and cats. Br. J. Ophthalmol. 1955; 39: 647–658
   PubMedGoogle Scholar
• Lewis R. A., Schoenwald R. D., Barfknecht C. F., Phelps C D. Aminozolamide gel; A trial of a topical carbonic anhydrase inhibitor in ocular hypertension. Arch. Ophthalmol. 1986; 104: 842–844
   PubMedGoogle Scholar
• Kalina P. H., Shetlar D. J., Lewis R. A., Kullerstrand L. J., Brubaker R. F. 6-Amino-2-benzothiazole-sulfonamide. The effect of a topical carbonic anhydrase inhibitor on aqueous humor formation in the normal human eye. Ophthalmol. 1988; 95: 772–777
   PubMed Web of Science ®Google Scholar
• Lee P-Y, Podos S. M., Serle J. B., Camras C. B., Severin C. H. Intraocular pressure effects of multiple doses of drugs applied to glaucomatous monkey eyes. Arch. Ophthalmol. 1987; 105: 249–252
   PubMedGoogle Scholar
• DeSantis L., Sallee V., Barnes G., Schoenwald R., Barfknecht C., Duffel M., Lewis R. The effect of topically applied analogs of the carbonic anhydrase inhibitor ethoxzolamide on intraocular pressure in alert laser-induced ocular hypertensive cynomolgus monkeys. Invest. Ophthalmol. Vis. Sci. (Suppl.) 1986; 27: 179
   Google Scholar
• Maren T. H., Bar-Ilan A. Ocular pharmacology and hypotensive activity of a topically active carbonic anhydrase (CA) inhibitor, a 4-alkylaminothienothiopyran-2-sulfonamide, MK-927. Invest. Ophthalmol. Vis. Sci. (Suppl.) 1988; 29: 16
   Google Scholar
• Hennekes R., Pfeiffer N., Lippa E., Garus H., Grehn F., Jaeger A. MK-927: An active topical carbonic anhydrase inhibitor in patients. Invest. Ophthalmol. Vis. Sci. (Suppl.) 1988; 29: 82
   Google Scholar